HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias.

Abstract
Chronic natural killer large granular lymphocyte (NK-LGL) leukemia, also referred to as chronic lymphoproliferative disorder of NK cells, is a rare disorder defined by prolonged expansion of clonal NK cells. Similar prevalence of STAT3 mutations in chronic T-LGL and NK-LGL leukemia is suggestive of common pathogenesis. We undertook whole-genome sequencing to identify mutations unique to NK-LGL leukemia. The results were analyzed to develop a resequencing panel that was applied to 58 patients. Phosphatidylinositol 3-kinase pathway gene mutations (PIK3CD/PIK3AP1) and TNFAIP3 mutations were seen in 5% and 10% of patients, respectively. TET2 was exceptional in that mutations were present in 16 (28%) of 58 patient samples, with evidence that TET2 mutations can be dominant and exclusive to the NK compartment. Reduced-representation bisulfite sequencing revealed that methylation patterns were significantly altered in TET2 mutant samples. The promoter of TET2 and that of PTPRD, a negative regulator of STAT3, were found to be methylated in additional cohort samples, largely confined to the TET2 mutant group. Mutations in STAT3 were observed in 19 (33%) of 58 patient samples, 7 of which had concurrent TET2 mutations. Thrombocytopenia and resistance to immunosuppressive agents were uniquely observed in those patients with only TET2 mutation (Games-Howell post hoc test, P = .0074; Fisher's exact test, P = .00466). Patients with STAT3 mutation, inclusive of those with TET2 comutation, had lower hematocrit, hemoglobin, and absolute neutrophil count compared with STAT3 wild-type patients (Welch's t test, P ≤ .015). We present the discovery of TET2 mutations in chronic NK-LGL leukemia and evidence that it identifies a unique molecular subtype.
AuthorsThomas L Olson, HeeJin Cheon, Jeffrey C Xing, Kristine C Olson, Umadevi Paila, Cait E Hamele, Yaseswini Neelamraju, Bryna C Shemo, Matt Schmachtenberg, Shriram K Sundararaman, Mariella F Toro, Cheryl A Keller, Emily A Farber, Suna Onengut-Gumuscu, Francine E Garrett-Bakelman, Ross C Hardison, David J Feith, Aakrosh Ratan, Thomas P Loughran
JournalBlood (Blood) Vol. 138 Issue 8 Pg. 662-673 (08 26 2021) ISSN: 1528-0020 [Electronic] United States
PMID33786584 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2021 by The American Society of Hematology.
Chemical References
  • DNA-Binding Proteins
  • Neoplasm Proteins
  • Dioxygenases
  • TET2 protein, human
Topics
  • Chronic Disease
  • DNA-Binding Proteins (blood, genetics)
  • Dioxygenases (blood, genetics)
  • Female
  • Humans
  • Leukemia, Large Granular Lymphocytic (blood, genetics)
  • Male
  • Mutation
  • Neoplasm Proteins (blood, genetics)
  • Registries

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: